HUTCHMED: Takeda. FDA Approval of FRUZAQLA™ (fruquintinib) for Colorectal Cancer

 — FRUZAQLA is the first targeted therapy approved in the U.S. for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in more than a decade —

— U.S. approval of FRUZAQLA triggers first milestone payment from Takeda of US$35 million and royalties on net sales —

https://www.biospace.com/article/releases/hutchmed-announces-that-takeda-receives-u-s-fda-approval-of-fruzaqla-fruquintinib-for-previously-treated-metastatic-colorectal-cancer/